Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
aaiPharma, AbbVie, academic, acid, Adcirca, Allergan, amino, analyze, arterial, automatically, Barovic, biggest, Biogen, biotech, broaden, calcitonin, carryforward, Celgene, CER, CGRP, cisplatin, clarification, closure, commensurate, concomitantly, consumption, County, Crohn, dampen, deal, disallowance, disinterested, displaced, DNA, docetaxel, ehf, elevated, empowered, encourage, energy, enrichment, equitable, Euronext, expansion, frequent, Gilead, Glenmark, hacking, HTA, hypertension, Idec, illustrated, immaterial, indemnification, indirect, ineffectual, injector, Kim, Korea, lodged, malware, Marion, MCO, media, Medtronic, NeoSan, nonclinical, notional, NYSE, opposition, outbreak, outlined, paclitaxel, PCORI, peglispro, pemetrexed, PRELUDE, prospective, pulmonary, purportedly, RAINBOW, Ratify, receipt, recombinant, refinancing, relapse, repatriated, REVEL, rolling, ROSE, salt, Sanofi, secret, sector, sequence, setoff, sharply, spinoff, SQUIRE, standalone, stemming, stored, Tai, talent, tanezumab, terrorism, thereof, thyroid, UK, uninterrupted, unjust, unspecified, voluntary, war, waste, weaker, wrongful
Removed:
AA, accessible, Acrux, aid, Alnara, amyloid, antitrust, Apralan, Armitage, array, ASU, Avid, Axid, bacterial, began, borrowed, brain, canine, categorized, cholesterol, collective, commercializing, compulsory, conjunction, cooperating, creditable, decertification, decertified, decertify, decided, defending, diet, discrete, disposing, divested, downturn, duloxetine, dyslipidemia, economy, Education, educational, enactment, enrollment, enteric, enzyme, Evonik, excise, excluding, exocrine, expiry, explore, FASB, florbetapir, goal, heightened, hoover, hyperlipidemia, ImClone, imposition, injunction, insufficiency, investigative, Lafayette, led, Livalo, London, matter, metabolic, modification, Moody, nonmonetary, norepinepherine, Northern, olanzapine, opposed, ordered, outlook, overtime, pathology, permanently, plaque, pose, positioning, Practice, preliminarily, preliminary, prepaid, prevented, pro, profitability, radiopharmaceutical, reclassification, Reconcile, reconsideration, recovered, repayment, represented, rest, restitution, reuptake, Robert, ruled, scan, separation, Sligo, software, sought, stream, streamline, strictly, subpoena, subsidy, Tippecanoe, tumor, update, upholding, utero, utilizing, violation, violative, voluntarily, waiting, weighted, West, Western, wide, worked
Filing tables
Filing exhibits
- 10-K Annual report
- 3.1 Amended Articles of Incorporation
- 10.5 the Lilly Deferred Compensation Plan
- 10.7 the Eli Lilly and Company Bonus Plan
- 12 Statement Re: Computation of Ratio of Earnings to Fixed Charges
- 21 List of Subsidiaries& Affiliates
- 23 Consent of Independent Registered Public Accounting Firm
- 31.1 Rule 13A-14(A) Certification of John C. Lechleiter, PH.D., Chairman of the Board
- 31.2 Rule 13A-14(A) Certification of Derica W. Rice, Executive Vice President, Global
- 32 SECTION1350 Certification
- Download Excel data file
- View Excel data file
Related press release
LLY similar filings
Filing view
External links
EXHIBIT 12. Statement Re: Computation of Ratio of Earnings to Fixed Charges
ELI LILLY AND COMPANY AND SUBSIDIARIES
| Years Ended December 31, | ||||||||||||||||||||
| 2013 | 2012 | 2011 | 2010 | 2009 | ||||||||||||||||
| (Dollars in millions) | ||||||||||||||||||||
| Consolidated pretax income | $ | 5,889.3 | $ | 5,408.2 | $ | 5,349.5 | $ | 6,525.2 | $ | 5,357.8 | ||||||||||
Interest(1) | 184.2 | 198.8 | 211.7 | 211.5 | 291.5 | |||||||||||||||
| Less interest capitalized during the period | (24.1 | ) | (21.0 | ) | (25.7 | ) | (26.0 | ) | (30.2 | ) | ||||||||||
| Earnings | $ | 6,049.4 | $ | 5,586.0 | $ | 5,535.5 | $ | 6,710.7 | $ | 5,619.1 | ||||||||||
| Fixed charges | $ | 184.2 | $ | 198.8 | $ | 211.7 | $ | 211.5 | $ | 291.5 | ||||||||||
| Ratio of earnings to fixed charges | 32.8 | 28.1 | 26.1 | 31.7 | 19.3 | |||||||||||||||
1 | Interest is based upon interest expense reported as such in the consolidated statements of operations and does not include any interest related to unrecognized tax benefits, which is included in income tax expense. |